Facebook Instagram Twitter RSS Feed PodBean Back to top on side

Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer

In: NEOPLASMA, vol. 64, no. 4
W. Wang - M. Liang - G. Ma - L. Li - W. Zhou - T. Xia - H. Xie - S. Wang
Detaily:
Rok, strany: 2017, 611 - 618
O článku:
Cell-free DNA integrity (cfDI) is a promising diagnostic and prognostic biomarker in breast cancer. However, no specific study has evaluated the diagnostic ability of cfDI in patients with no distant metastasis breast cancer (no-MBC) and benign breast tumor (BBT) to date. We assessed the plasma cfDI of 84 patients with no-MBC and 30 patients with BBT using quantitative PCR and compared it with circulating tumor cells (CTCs) and carbohydrate antigen 153 (CA153). The no-MBC group had significantly lower mean cfDI (0.58) than the BBT group (0.74, p = 0.004). Subgroup analysis showed that decreased cfDI seem to be associated with risk factors such as age 14% (mean cfDI = 0.57), tumor size > 2 cm (mean cfDI = 0.58), and positive lymph node status (mean cfDI = 0.56), but had no statistical significance. McNemar’s test suggested that cfDI had stronger diagnostic power than CTCs, cfDNA concentration, or CA153 (p < 0.001). Spearman’s rho showed that the correlation coefficient between cfDI and CTCs was 0.278 (p = 0.04) in the no-MBC group. Receiver operating characteristic curve analysis also suggested that cfDI was superior to CTCs or CA153. Combined with CTCs, cfDI reduced the false positive rate from 50% to 10.71% and increased the area under the curve value from 0.66 to 0.68. Our results suggest that cfDI is a potential diagnostic biomarker of no-MBC. Using cfDI and CTCs as a combined diagnostic tool for no-MBC could improve diagnostic sensitivity and specificity but more samples will be needed. Keywords: cell-free DNA, cell-free DNA integrity, circulating tumor cell, no distant metastasis breast cancer
Ako citovať:
ISO 690:
Wang, W., Liang, M., Ma, G., Li, L., Zhou, W., Xia, T., Xie, H., Wang, S. 2017. Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer. In NEOPLASMA, vol. 64, no.4, pp. 611-618. 0028-2685.

APA:
Wang, W., Liang, M., Ma, G., Li, L., Zhou, W., Xia, T., Xie, H., Wang, S. (2017). Plasma cell-free DNA integrity plus circulating tumor cells: a potential biomarker of no distant metastasis breast cancer. NEOPLASMA, 64(4), 611-618. 0028-2685.